Defining "adequate" pathogen reduction performance for transfused blood components

Transfusion

Volumn 50, Issue 8, 2010, Pages 1827-1837

  Goodrich, Raymond P ^a,b   Custer, Brian ^a,b   Keil, Shawn ^a,b   Busch, Michael ^a,b  

^a CaridianBCT Biotechnologies LLC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL GROWTH; BACTERIAL TRANSMISSION; BACTERIUM CONTAMINATION; BLOOD ANALYSIS; BLOOD COMPONENT; BLOOD TRANSFUSION; COLONY FORMING UNIT; ERYTHROCYTE TRANSFUSION; HEAT TREATMENT; HUMAN; MEDICAL INSTRUMENTATION; NONHUMAN; NOTE; PARASITE; PARASITEMIA; PLASMA; THROMBOCYTE TRANSFUSION; ULTRACENTRIFUGATION; VIRAL CONTAMINATION; VIREMIA; VIRUS TRANSMISSION; BACTEREMIA; BLOOD COMPONENT THERAPY; BLOODBORNE BACTERIUM; ISOLATION AND PURIFICATION; MICROBIOLOGY; PARASITOLOGY; VIROLOGY; VIRUS REPLICATION;

BACTEREMIA; BLOOD COMPONENT TRANSFUSION; BLOOD-BORNE PATHOGENS; HUMANS; PARASITEMIA; VIREMIA; VIRUS REPLICATION;

EID: 77955127865     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02635.x     Document Type: Note

References (52)

1. Piet MP, Chin S, Prince AM, Brotman B, Cundell AM, Horowitz B. The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion 1990 30 : 591 8.
2. Miller JL, Petteway SR Jr., Lee DC. Ensuring the pathogen safety of intravenous immunoglobulin and other human plasma-derived therapeutic proteins. J Allergy Clin Immunol 2001 108 Suppl : S91 S94.
3. Kempf C, Stucki M, Boschetti N. Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins. Biologicals 2007 35 : 35 42.
4. Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 2003 43 : 1322 9.
5. Amotosalen: allogeneic cellular immunotherapies system, INTERCEPT plasma system, INTERCEPT platelet system, S 59. BioDrugs 2003 17 : 66 8.
6. Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006 35 : 5 17.
7. Goodrich RP, Doane S, Reddy HL. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals. In press 2009, doi:10.1016/j.biologicals. 2009.10.016
8. Fast L, Marschner S, DiLeone G, Doane S, Fitzpatrick C, Goodrich R. Functional inactivation of human white blood cells in whole blood products using the Mirasol system for whole blood. 61st AABB Annual Meeting, Montreal, Quebec, Canada, October 4-7, 2008. Transfusion 2008 48 : S2, 229A.
9. Reddy H, Doane S, Fitzpatrick C, Goodrich R. Forty-two-day storage of RBCs from whole blood treated with the Mirasol® System. 61st AABB Annual Meeting, Montreal, Quebec, Canada, October 4-7, 2008. Transfusion 2008 48 : S2, 229A.
10. Reddy H, Doane S, Fitzpatrick C, Goodrich R. Platelet concentrates and fresh frozen plasma from whole blood treated with the Mirasol® System. 61st AABB Annual Meeting, Montreal, Quebec, Canada, October 4-7, 2008. Transfusion 2008 48 : S2, 231A.
11. Doane S, Reddy H, Fitzpatrick C, Goodrich R. Hemolysis and methemoglobin in Mirasol® treated whole blood during storage at room temperature. 61st AABB Annual Meeting, Montreal, Quebec, Canada, October 4-7, 2008. Transfusion 2008 48 : S2, 230A.
12. Doane S, Reddy H, Fitzpatrick C, Keil S, Goodrich R. Evaluation of pathogen reduction in whole blood with the Mirasol® system for whole blood. 61st AABB Annual Meeting, Montreal, Quebec, Canada, October 4-7, 2008. Transfusion 2008 48 : S2, 87A.
13. The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit. The design, contribution and interpretation of studies validating the inactivation and removal of viruses. CPMP/BWP/268/95 1996 Feb 14.
14. Horowitz B, Busch M. Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin. Transfusion 2008 48 : 1739 53.
15. Horowitz B, Lazo A, Grossberg H, Page G, Lippin A, Swan G. Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang 1998 74 Suppl 1 : 203 6.
16. Fratantoni JC, Prodouz KN, Horowitz MS. Viral inactivation of blood products. Transfusion 1990 30 : 480 1.
17. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005 45 : 254 64.
18. Weusten JJ, van Drimmelen HA, Lelie PN. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion 2002 42 : 537 48.
19. Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009 49 : 2454 89.
20. Coste J. [Screening for viral genomes in blood transfusion]. Transfus Clin Biol 2000 7 Suppl 1 : 11s 7s.
21. Busch MP, Kleinman SH, Tobler LH, Kamel HT, Norris PJ, Walsh I, Matud JL, Prince HE, Lanciotti RS, Wright DJ, Linnen JM, Caglioti S. Virus and antibody dynamics in acute West Nile virus infection. J Infect Dis 2008 198 : 984 93.
22. Ness PM. An incremental solution to bacterial contamination: taking the first step. Transfusion 2004 44 : 311 2.
23. Blajchman MA, Beckers EA, Dickmeiss E, Lin L, Moore G, Muylle L. Bacterial detection of platelets: current problems and possible resolutions. Transfus Med Rev 2005 19 : 259 72.
24. Blajchman MA. Incidence and significance of the bacterial contamination of blood components. Dev Biol (Basel) 2002 108 : 59 67.
25. Brecher ME, Hay SN. Bacterial contamination of blood components. Clin Microbiol Rev 2005 18 : 195 204.
26. Lee J US Food and Drug Administration. Presented at the FDA/CBER workshop on contamination of platelets. 1999. Available from: URL: http://www.FDA.gov/ downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/ TranscripsMinutes/UCM055446.pdf
27. Jafari M, Forsberg J, Gilcher RO, Smith JW, Crutcher JM, McDermott M, Brown BR, George JN. Salmonella sepsis caused by a platelet transfusion from a donor with a pet snake. N Engl J Med 2002 347 : 1075 8.
28. de Korte D, Curvers J, de Kort WL, Hoekstra T, van der Poel CL, Beckers EA, Marcelis JH. Effects of skin disinfection method, deviation bag, and bacterial screening on clinical safety of platelet transfusions in the Netherlands. Transfusion 2006 46 : 476 85.
29. de Korte D, Marcelis JH, Verhoeven AJ, Soeterboek AM. Diversion of first blood volume results in a reduction of bacterial contamination for whole-blood collections. Vox Sang 2002 83 : 13 6.
30. McDonald CP, Roy A, Mahajan P, Smith R, Charlett A, Barbara JA. Relative values of the interventions of diversion and improved donor-arm disinfection to reduce the bacterial risk from blood transfusion. Vox Sang 2004 86 : 178 82.
31. Eder AF, Kennedy JM, Dy BA, Notari EP, Skeate R, Bachowski G, Mair DC, Webb JS, Wagner SJ, Dodd RY, Benjamin RJ the American Red Cross Regional Blood Centers. Limiting and detecting bacterial contamination of apheresis platelets: inlet-line diversion and increased culture volume improve component safety. Transfusion 2009 49 : 1554 63.
32. Bruneau C, Perez P, Chassaigne M, Allouch P, Audurier A, Gulian C, Janus G, Boulard G, de Micco P, Salmi LR, Noel L. Efficacy of a new collection procedure for preventing bacterial contamination of whole-blood donations. Transfusion 2001 41 : 74 81.
33. Wagner SJ, Robinette D, Friedman LI, Miripol J. Diversion of initial blood flow to prevent whole-blood contamination by skin surface bacteria: an in vitro model. Transfusion 2000 40 : 335 8.
34. Silva MA, Gregory KR, Carr-Greer MA, Holmberg JA, Kuehnert MJ, Brecher ME. Summary of the AABB interorganizational task force on bacterial contamination of platelets: Fall 2004 impact survey. Transfusion 2006 46 : 636 41.
35. Brecher ME, Hay SN, Rothenberg SJ. Validation of BacT/ALERT plastic culture bottles for use in testing of whole-blood-derived leukoreduced platelet-rich-plasma-derived platelets. Transfusion 2004 44 : 1174 8.
36. Wagner SJ, Eder AF. A model to predict the improvement of automated blood culture bacterial detection by doubling platelet sample volume. Transfusion 2007 47 : 430 3.
37. Benjamin RJ, Wagner SJ. The residual risk of sepsis: modeling the effect of concentration on bacterial detection in two-bottle culture systems and an estimation of false-negative culture rates. Transfusion 2007 47 : 1381 9.
38. Lai M, Rumi C, D'Onofrio G, Puggioni PL, Menichella G, Candido A, Leone G. Phosphatidylserine exposure in platelet concentrates during the storage period: differences between the platelets collected with different cell separators. Transfus Apher Sci 2002 27 : 239 45.
39. Brecher ME, Holland PV, Pineda AA, Tegtmeier GE, Yomtovian R. Growth of bacteria in inoculated platelets: implications for bacteria detection and the extension of platelet storage. Transfusion 2000 40 : 1308 12.
40. Goodrich RP, Gilmour D, Hovenga N, Keil SD. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009 49 : 1205 16.
41. McKenzie FE, Jeffery GM, Collins WE. Plasmodium vivax blood-stage dynamics. J Parasitol 2002 88 : 521 35.
42. Hermsen CC, de Vlas SJ, van Gemert GJ, Telgt DS, Verhage DF, Sauerwein RW. Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. Am J Trop Med Hyg 2004 71 : 196 201.
43. Schenone H, Rojas A. [Longitudinal study, by xenodiagnosis, of parasitemia in patients with chronic Trypanosoma cruzi infection]. Bol Chil Parasitol 1999 54 : 29 32.
44. Cucunuba ZM, Guerra AP, Rahirant SJ, Rivera JA, Cortes LJ, Nicholls RS. Asymptomatic Plasmodium spp. infection in Tierralta, Colombia. Mem Inst Oswaldo Cruz 2008 103 : 668 73.
45. Andrade LO, Andrews NW. The Trypanosoma cruzi-host-cell interplay: location, invasion, retention. Nat Rev Microbiol 2005 3 : 819 23.
46. Sanchez NO, Mora MC, Basombrio MA. High prevalence of congenital Trypanosoma cruzi infection and family clustering in Salta, Argentina. Pediatrics 2005 115 : e668 e672.
47. Triulzi D, Duquesnoy R, Nichols L, Clark K, Jukic D, Zeevi A, Meisner D. Fatal transfusion-associated graft-versus-host disease in an immunocompetent recipient of a volunteer unit of red cells. Transfusion 2006 46 : 885 8.
48. Blajchman MA. Immunomodulatory effects of allogeneic blood transfusions: clinical manifestations and mechanisms. Vox Sang 1998 74 Suppl 2 : 315 9.
49. Fast LD, DiLeone G, Li J, Goodrich R. Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006 46 : 642 8.
50. Asano H, Lee CY, Fox-Talbot K, Koh CM, Erdinc MM, Marschner S, Keil S, Goodrich RP, Baldwin WM. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007 84 : 1174 82.
51. Reddy H, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich R. Toxicity testing of the Mirasol PRT process for platelets and plasma: a novel riboflavin-based pathogen reduction technology for blood transfusion safety. Transfus Med Rev 2008 22 : 133 53.
52. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005 45 : 1335 41.